Timing Matters: Radiotherapy Within Six Weeks Reshapes Outcomes After Incomplete Spinal Ependymoma Surgery

Spinal ependymomas are rare tumors arising from the ependymal cells that line the central canal of the spinal cord, and for decades the question of what to do after surgery has divided neuro-oncologists. A new multicenter study from the Turkish Radiation Oncology Digital (TROD) Neuro-Oncology research group, published in the Journal of Neuro-Oncology, offers one of the most detailed long-term pictures yet of how adults with these tumors fare after adjuvant radiotherapy, and its central finding is strikingly practical: when a surgeon cannot remove the entire tumor, the clock starts ticking, and every week of delay before radiotherapy may matter. Drawing on 45 adult patients treated across ten Turkish institutions between 1998 and 2024, the researchers found that a surgery-to-radiotherapy interval longer than 1.5 months was the single strongest independent predictor of early recurrence in patients left with residual disease, carrying hazard ratios of 13.3 for disease-free survival and 15.9 for progression-free survival.

The study, led by Ertugrul Senturk and Petek Erpolat of Gazi University Faculty of Medicine in Ankara, was designed to address a persistent evidence gap. Spinal ependymomas account for a substantial share of intramedullary spinal cord tumors in adults, yet no randomized trial has ever defined the optimal adjuvant strategy, and guidelines from the European Association of Neuro-Oncology acknowledge that recommendations for radiotherapy after subtotal resection rest on limited retrospective data. The TROD investigators restricted their analysis to adults aged 18 or older with histologically confirmed World Health Organization Grade 2 or Grade 3 tumors, excluding Grade 1 lesions such as myxopapillary ependymomas and any patient whose radiotherapy began more than six months after surgery, in order to create a analytically coherent cohort in which the timing question could be examined cleanly.

The methodological backbone of the study was conventional but rigorous. Clinical outcomes were estimated with Kaplan-Meier survival analysis, and prognostic factors were tested in multivariate Cox regression models, allowing the investigators to separate the independent contribution of each variable from the confounding influence of the others. Endpoints included local control, disease-free survival, progression-free survival, and overall survival, with local failure defined according to modern neuro-oncology response assessment criteria. With a median follow-up of 7.9 years in the Grade 2 cohort, the dataset offers something genuinely rare in this disease: a decade-scale view of what happens after adjuvant irradiation.

The dominant message from the Grade 2 cohort, which comprised 37 of the 45 patients, is that the extent of surgical resection remains the primary determinant of disease control. Gross total resection was achieved in 43.2 percent of these patients, and the results in that group were extraordinary: not a single local failure occurred, translating into 100 percent ten-year local control and disease-free survival. Among patients whose tumors were only subtotally resected, by contrast, 41.2 percent eventually experienced local failure, with five- and ten-year disease-free survival of 63.9 percent and 54.7 percent respectively, a difference that reached statistical significance at p = 0.006. In other words, even in an era when adjuvant radiotherapy is available, nothing the radiation oncologist delivers fully substitutes for a complete surgical excision when it can be achieved safely.

Yet the story is not simply one of surgery versus radiation. Despite the dramatic difference in local control, overall survival was statistically indistinguishable between the two resection groups, with ten-year overall survival of 88.9 percent after gross total resection versus 74.3 percent after subtotal resection, a difference that failed to reach significance at p = 0.70. This divergence between local control and survival underscores a clinical reality familiar to neuro-oncologists: spinal ependymomas often recur locally and slowly, and salvage treatment can extend life even when the initial disease control is imperfect. It also suggests that adjuvant radiotherapy, delivered to patients with residual disease, does meaningful work in suppressing local regrowth even if the ultimate survival benefit is harder to demonstrate in a cohort of this size.

The most consequential finding, however, concerns timing. Among non-GTR patients who had no evidence of tumor dissemination at the start, a surgery-to-radiotherapy interval exceeding 1.5 months emerged as the sole independent predictor of early recurrence, with the enormous hazard ratios noted above reaching significance at p = 0.04 for both disease-free and progression-free survival. The authors conclude that early adjuvant radiotherapy, ideally initiated within about six weeks of surgery, should be regarded as a critical management strategy for patients with residual Grade 2 disease. Because this was a retrospective analysis, the result cannot prove causation in the way a randomized trial could, and patients referred late for radiotherapy may differ in ways the models cannot fully capture. Even so, a signal this strong, in the largest direction imaginable, gives treating physicians a concrete, actionable benchmark in a field that has operated largely on intuition.

The study also clarified which patients face the steepest odds regardless of treatment. Younger age at diagnosis and the presence of baseline spinal dissemination were both independent adverse prognostic factors for progression and mortality. For patients who presented with spinal dissemination at the outset, the progression rate reached 60 percent and median overall survival collapsed to just 15.2 months, a sobering figure that illustrates how quickly this disease can shift from an indolent, surgically manageable problem to a disseminated, life-threatening one. These findings argue for careful baseline neuraxis imaging and heightened surveillance in any patient whose tumor has already seeded the cerebrospinal fluid pathways.

Grade 3, or anaplastic, ependymomas behaved very differently. In this small subgroup, five-year local control, progression-free survival, and overall survival were 56.3 percent, 41.7 percent, and 75.0 percent respectively, and 62.5 percent of patients progressed. Interestingly, gross total resection did achieve complete local control even in these aggressive tumors, but distant metastasis remained the dominant pattern of failure, occurring in 60 percent of progressive cases. This dissociation between local and distant control carries an important implication: for anaplastic tumors, excellent local therapy is not enough, and the field may need to think in terms of systemic or craniospinal strategies to address the risk of dissemination, an area where current evidence remains thin and clinical trials are urgently needed.

The technical details of the radiation itself matter as well, even though the published abstract centers on timing and extent of resection. Modern practices, including image-guided and increasingly stereotactic approaches to the spine, allow high conformal doses to be delivered to residual tumor while sparing the exquisitely radiation-sensitive spinal cord, and the study’s data collection aligned with standard toxicity grading frameworks to capture treatment-related harm. The authors report no funding sources and no competing interests, and the dataset is available from the corresponding author upon reasonable request, inviting external validation of their findings.

What should patients and clinicians take away from this work? First, gross total resection remains the gold standard, and every effort should be made to achieve it when it can be done without unacceptable neurological risk, an aim increasingly supported by intraoperative neuromonitoring. Second, when residual disease is left behind, adjuvant radiotherapy demonstrably provides effective local control in Grade 2 tumors, and delaying it beyond roughly six weeks appears to carry a substantial and measurable cost in recurrence risk. Third, Grade 3 histology and initial spinal dissemination mark patients for intensified surveillance and, plausibly, for future trials of more aggressive combined-modality therapy. In a rare disease where no single institution will ever accumulate enough patients to answer these questions alone, the multicenter TROD model itself deserves credit: by pooling nearly three decades of experience across ten centers, the group has produced one of the clearest evidence-based guides yet for a treatment dilemma that neurosurgeons and radiation oncologists confront every week.

Subject of Research: Long-term outcomes of adjuvant radiotherapy in adult WHO Grade 2 and 3 spinal ependymomas

Article Title: Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005)

Article References: Senturk, E., Erpolat, P., Kamer, S., Yücel, B., Barış, B. Ş., Bayatfard, P., Atasoy, B., Çetinayak, H. O., Atasever Akkaş, E., Baltalarlı, P. B., & Delikgöz Soykut, E. (2026). Long-term outcomes after adjuvant radiotherapy in adult spinal ependymomas: a multicenter study by the trod Neuro-Oncology research group (07 − 005). Journal of Neuro-Oncology, 179(2), Article 77. https://doi.org/10.1007/s11060-026-05793-z

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05793-z

Keywords: spinal ependymoma, adjuvant radiotherapy, gross total resection, subtotal resection, local control, disease-free survival, progression-free survival, overall survival, anaplastic ependymoma, spinal dissemination, recurrence timing, neuro-oncology